Key Executives
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Dr. Steven A. Nichtberger M.D. | Co-Founder, Chairman, CEO & President | 1.02M | -- | 1961 |
| Dr. David J. Chang FACR, M.D., M.P.H. | Chief Medical Officer | 721.85k | -- | 1963 |
| Dr. Gwendolyn K. Binder Ph.D. | President of Science & Technology | 722.62k | -- | 1975 |
| Dr. Michael C. Milone M.D., Ph.D. | Co-Founder & Co-Chair of Scientific Advisory Board | -- | -- | -- |
| Dr. Aimee Payne M.D., Ph.D. | Co-Founder & Co-Chair of Scientific Advisory Board | -- | -- | -- |
| Mr. Anup Marda M.B.A. | Chief Financial Officer | 548.2k | -- | 1978 |
| Dr. Qing Sarah Yuan Ph.D. | Chief Technology Officer | -- | -- | 1971 |
| Dr. Samik Basu M.D. | Chief Scientific Officer | -- | -- | -- |
| Mr. Michael Gerard J.D. | General Counsel & Secretary | -- | -- | 1980 |
| Ms. Heather Harte-Hall M.Sc. | Chief Compliance Officer | -- | -- | -- |
Cabaletta Bio, Inc.
- Sector:
- Healthcare
- Industry: Biotechnology
- Full Time Employees:
- 136
Description
Cabaletta Bio, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases. The company's lead product candidate is CABA-201, a fully human anti-CD19 binder for the treatment of Phase 1/2 clinical trials in dermatomyositis, anti-synthetase syndrome, immune-mediated necrotizing myopathy, lupus nephritis, non-renal systemic lupus erythematosus, systemic sclerosis, and generalized myasthenia gravis. It also develops DSG3-CAART, which is in Phase I/II clinical trial for the treatment of mucosal pemphigus vulgaris; and MuSK-CAART, an investigational cell therapy that is in Phase I/II clinical trial for treating patients with anti- muscle-specific kinase antibody positive myasthenia gravis. It has a collaboration with the University of Pennsylvania and the Children's Hospital of Philadelphia; Nanjing IASO Biotherapeutics Co., Ltd; Oxford Biomedica; and WuXi Advanced Therapies, Inc. The company was formerly known as Tycho Therapeutics, Inc. and changed its name to Cabaletta Bio, Inc. in August 2018. Cabaletta Bio, Inc. was incorporated in 2017 and is headquartered in Philadelphia, Pennsylvania.
Corporate Governance
Upcoming Events
March 19, 2025 at 12:30 PM UTC - March 24, 2025 at 12:30 PM UTC
Cabaletta Bio, Inc. Earnings Date